GlassScriptPhysician profile
Hong Chen
NPI 1689921934
$56,510.67
in general payments reported to CMS, 2019-2025
26 companies · $9,509 in 2025
The $9,509 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11K · 2022: $11K · 2023: $7,042 · 2024: $19K · 2025: $9,509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Food and Beverage: $12K · Travel and Lodging: $4,304 · Consulting Fee: $2,325 · Education: $10.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,600.00 |
| Food and Beverage | $12,133.03 |
| Travel and Lodging | $4,304.29 |
| Consulting Fee | $2,325.00 |
| Education | $10.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $22,331.43 | 2021-2025 | Vemlidy |
| Phathom Pharmaceuticals, INC. | $10,826.38 | 2023-2025 | Voquezna |
| Ibsa Pharma INC. | $4,700.56 | 2021-2025 | Licart, Tirosint, Licart |
| Abbvie INC. | $2,851.00 | 2021-2025 | |
| Esperion Therapeutics, INC. | $2,320.80 | 2021-2025 | Nexletol |
| Biohaven Pharmaceuticals, INC. | $2,084.29 | 2021 | |
| Amgen INC. | $1,947.85 | 2021-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,503.48 | 2021-2025 | Jardiance, Spiriva Respimat, Synjardy |
| Astrazeneca Pharmaceuticals LP | $1,258.00 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $1,002.25 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $989.47 | 2022-2025 | Arexvy, Nucala, Shingrix |
| Biohaven Pharmaceutical Holding Company LTD. | $804.12 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $727.32 | 2021-2025 | Xifaxan, Trulance |
| Horizon Therapeutics Plc | $697.35 | 2021-2023 | Krystexxa |
| Amarin Pharma, INC. | $575.90 | 2021-2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $386.51 | 2022-2024 | |
| Aimmune Therapeutics, INC. | $342.31 | 2024-2025 | Zenpep |
| Bayer Healthcare Pharmaceuticals INC. | $259.60 | 2022-2024 | |
| Lilly USA, LLC | $252.41 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Nestle Healthcare Nutrition INC. | $161.54 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $160.92 | 2022-2024 | |
| Ironwood Pharmaceuticals, INC | $113.41 | 2023-2024 | Linzess |
| Sumitomo Pharma America, INC. | $79.71 | 2025 | Gemtesa |
| Corcept Therapeutics | $67.21 | 2025 | Korlym |
| Biogen, INC. | $53.33 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $13.52 | 2024 | Onivyde |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hong Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.